why choose us

First received: May 12, 2023

Clinical Trial: ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

Study Status: Completed

Recruit Status: RECRUITING

Condition: X-linked Retinoschisis

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety and Tolerability of ATSN-201 Gene Therapy in Male Subjects With RS1-Associated X-linked Retinoschisis

Brief Summary: This study will evaluate the safety and tolerability of ATSN-201 in male subjects 6 to 64 years old with RS1-associated X-linked retinoschisis (XLRS).

Read more